At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
-
Researchers want to find the best dose of abemaciclib to combine with radiation therapy to treat advanced breast cancer. The people in this study have metastatic breast cancer that is fueled by estrogen or progesterone (hormone receptor-positive cancer). In addition, their breast cancer does not make a protein called HER2.
-
Researchers are comparing different sequences of therapy for people with newly diagnosed multiple myeloma. All participants will get cilta-cel CAR T-cell therapy, a form of immunotherapy made from your own white blood cells.
-
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
-
Researchers are seeking the best dose of raludotatug deruxtecan (R-DXd) for people with ovarian cancer when given with standard chemotherapy. The people in this study have ovarian cancer that came back after chemotherapy that included a platinum-containing drug.
-
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
-
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
- A Study of LY4257496 in People With Solid Tumor Cancer
Full Title OMNIRAY, A Phase 1a/b Multicenter, Open-Label Trial to Evaluate Safety, Tolerability, and Dosimetry of LY4257496, a GRPR-Targeted Radioligand Therapy, in Adults with GRPR-Positive Advanced Solid Tumors
Purpose
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Contact
For more information or to see if you can join this study, please call Dr. Komal Jhaveri’s office at 646-888-4226.
Protocol
25-361Phase
Phase I (phase 1)Investigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT07114601ClinicalTrials.gov
- A Phase 1 Study of PYX-201 in People With Advanced Solid Tumors
Full Title A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PYX-201 in Participants with Advanced Solid Tumors
Purpose
Researchers are evaluating PYX-201 in people with solid tumors that have spread and keep growing after treatment. The people in this study have these cancers:
- Head and neck cancer
- Thyroid cancer
- Salivary gland cancer
- Sarcoma chordoma
- Breast cancer
PYX-201 is an antibody-drug conjugate (ADC). ADCs are made up of an antibody linked to a drug. The antibody binds to specific proteins on cancer cells. The linked drug enters these cells and kills them, with a reduced risk of harming other cells.
By destroying these cells, PYX-201 may help slow or stop the growth of your cancer. It is given intravenously (by vein).
Who Can Join
To join this study, there are a few conditions. You must:
- Have one of the cancers listed above, which continues to grow despite treatment.
- Have recovered from the serious side effects of prior therapies before getting PYX-201.
- Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
- Be age 18 or older.
Contact
For more information or to see if you can join this study, please call Dr. Winston Wong’s office at 646-608-4245.
Protocol
25-265Phase
Phase I (phase 1)Investigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT05720117ClinicalTrials.gov
-
This study is assessing the safety and effectiveness of giving tucatinib and trastuzumab followed by standard CAPOX chemotherapy (the drugs capecitabine and oxaliplatin) in people with locally advanced rectal cancer that has not yet been treated and makes a protein called HER2. Tucatinib and trastuzumab both block HER2, which stimulates cancer cell growth.
-
The purpose of this study is to find the highest dose of the investigational drug RLY-2608 that can be used alone in people with advanced solid tumors and with fulvestrant in people with advanced breast cancer. Participants in this study will have cancers that contain a mutation in a gene called PIK3CA. Their cancers must have continued to grow despite treatment or be inoperable.